Indaptus Therapeutics (INDP)
NASDAQ:INDP
Want to see INDP full AI Analyst Report?
Top Page
Indaptus Therapeutics
(NASDAQ:INDP)
Select Model
Select Model
Rating:53Neutral
Price Target:
$3.50
▲(28.68% Upside)
Action:Reiterated
Date:06/12/26
The score is held back primarily by weak financial performance (pre-revenue losses, ongoing cash burn, and a shrinking equity base). Technicals are comparatively supportive with price above major moving averages and positive MACD, while valuation is constrained by negative earnings and no dividend support; recent governance-focused board additions provide a modest offset.
Positive Factors
Low Leverage / Financial Risk
Near-zero debt materially reduces financing fixed-cost risk for a pre-revenue biotech. Structurally, low leverage gives management flexibility to prioritize R&D or negotiate bridge financings without large interest burdens, preserving optionality over the next several months.
Negative Factors
Pre-revenue Business Model
No product revenue means all value depends on development milestones and external funding. Structurally, lack of commercial cash flow leaves margins undefined and creates sustained reliance on capital markets, raising execution and funding risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Financial Risk
Near-zero debt materially reduces financing fixed-cost risk for a pre-revenue biotech. Structurally, low leverage gives management flexibility to prioritize R&D or negotiate bridge financings without large interest burdens, preserving optionality over the next several months.
Read all positive factors
Indaptus Therapeutics (INDP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$404.28M
Dividend YieldN/A
Average Volume (3M)1.08M
Price to Earnings (P/E)―
Beta (1Y)1.92
Revenue GrowthN/A
EPS Growth61.43%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.34
Shares Outstanding113,242,325
10 Day Avg. Volume869,867
30 Day Avg. Volume1,084,648
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.89
Price to Sales (P/S)0.00
P/FCF Ratio-0.19
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.34
Revenue Forecast (FY)N/A
Indaptus Therapeutics Business Overview & Revenue Model
Company Description
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compou...
Indaptus Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -18.86M | -20.85M | -15.02M | -15.42M | -14.32M | -7.71M |
| Net Income | -18.86M | -20.85M | -15.02M | -15.42M | -14.32M | -7.71M |
Balance Sheet | ||||||
| Total Assets | 2.18M | 9.31M | 7.34M | 14.92M | 28.06M | 40.58M |
| Cash, Cash Equivalents and Short-Term Investments | 1.50M | 8.51M | 5.79M | 13.36M | 26.43M | 39.13M |
| Total Debt | 0.00 | 0.00 | 84.16K | 175.05K | 80.49K | 169.33K |
| Total Liabilities | 933.00K | 6.16M | 3.39M | 2.85M | 3.43M | 4.68M |
| Stockholders Equity | 1.25M | 3.15M | 3.94M | 12.08M | 24.63M | 35.90M |
Cash Flow | ||||||
| Free Cash Flow | -17.27M | -14.82M | -12.32M | -13.41M | -13.25M | -11.29M |
| Operating Cash Flow | -17.27M | -14.82M | -12.32M | -13.41M | -13.08M | -11.29M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 17.14M | -16.43M | 447.75K |
| Financing Cash Flow | 14.88M | 17.54M | 4.75M | 0.00 | 0.00 | 48.34M |
Indaptus Therapeutics Technical Analysis
Positive
2.72
Price Trends
2.26
Positive
2.11
Positive
2.59
Positive
Market Momentum
0.25
Negative
60.33
Neutral
27.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INDP, the sentiment is Positive. The current price of 2.72 is above the 20-day moving average (MA) of 2.01, above the 50-day MA of 2.26, and above the 200-day MA of 2.59, indicating a bullish trend. The MACD of 0.25 indicates Negative momentum. The RSI at 60.33 is Neutral, neither overbought nor oversold. The STOCH value of 27.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INDP.
Indaptus Therapeutics Risk Analysis
Indaptus Therapeutics disclosed 64 risk factors in its most recent earnings report. Indaptus Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Indaptus Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $404.28M | -0.41 | -1028.81% | ― | ― | 61.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $6.87M | -3.08 | -60.33% | ― | 23.52% | 48.34% | |
44 Neutral | $308.97M | -15.45 | -36.79% | ― | ― | 88.03% | |
| ― | $5.40M | -1.05 | -165.94% | ― | -70.00% | 14.70% |
* Healthcare Sector Average
INDP
Indaptus Therapeutics
3.57
-5.92
-62.38%
PALI
Palisade Bio
1.78
1.09
157.97%
TCRT
Alaunos Therapeutics
2.21
-0.79
-26.33%
XBIO
Xenetic Biosciences
3.00
-0.24
-7.41%
XAGE
Longevity Health Holdings
0.26
-2.38
-90.15%
Indaptus Therapeutics Corporate Events
Executive/Board Changes
Indaptus Therapeutics Announces Recent Board and Leadership Changes
Neutral
Jun 5, 2026
Indaptus Therapeutics, Inc. announced leadership changes effective June 2026, with directors David E. Lazar and Avraham Ben‑Tzvi resigning from all board and committee roles as of June 5, 2026. The company also reported that Chief Operating ...
Executive/Board Changes
Indaptus Therapeutics Adds Independent Directors Amid Board Refresh
Positive
Apr 23, 2026
On April 17, 2026, Indaptus Therapeutics, Inc. appointed financial executive Tim Ruan and intellectual property expert Dr. Yi Zhang as independent directors, effective April 22, 2026, strengthening the board with capital markets and life sciences ...
Business Operations and StrategyExecutive/Board Changes
Indaptus Therapeutics Names New CFO, Refreshes Board Oversight
Neutral
Apr 3, 2026
On April 1, 2026, Indaptus Therapeutics announced that Chief Financial Officer Nir Sassi resigned from his role, with the company stating that the departure did not stem from any disagreement over its operations, policies, or practices. That same ...
Executive/Board Changes
Indaptus Therapeutics Announces Major Leadership and Board Changes
Neutral
Mar 24, 2026
On March 18, 2026, Indaptus Therapeutics underwent a major leadership reshuffle as directors Jeffrey A. Meckler, Roger J. Pomerantz, Anthony J. Maddaluna, and William B. Hayes resigned, with Meckler and David Lazar also stepping down as co-chief e...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.